BioPharma Credit PLC
15 September 2026
15 September 2026
BIOPHARMA CREDIT PLC
(The "Company")
Appointment of New Director
The Board of Directors of the Company is pleased to announce the appointment of Graeme Proudfoot as a non-executive Director with effect from 15 September 2026.
Mr Proudfoot has considerable asset management experience and expertise, having spent the majority of his executive career at Invesco, latterly as Managing Director, EMEA and Chief Executive Officer of Invesco Pensions. Prior to joining Invesco, Graeme began his career at Wilde Sapte Solicitors, practising as a corporate finance lawyer in London and New York. He previously served as a director of VPC Specialty Lending Investments plc.
Mr Proudfoot is Chairman and non-executive Director of BlackRock Income & Growth Investment Trust and a non-executive Director of The Schiehallion Fund.
The Company makes this announcement in accordance with UKLR 6.4.6. There are no other matters to be disclosed under UKLR 6.4.8.
Enquiries:
BioPharma Credit plc
via MUFG Corporate Governance Limited
Company Secretary
+44 (0) 333 300 1932
Burson Buchanan
Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
LEI: 213800AV55PYXAS7SY24
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist debt investor from life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.